Acumen Pharmaceuticals, Inc. (ABOS): who owns it and who trades it
As of Nov 16, 2026, ABOS insiders reported 42 open-market sales worth $592K and no purchases in the last 12 months, with 15% of the sale value made under pre-set 10b5-1 plans. The largest seller was Derek M Meisner (Chief Legal Officer & Co), with $238K. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Acumen Pharmaceuticals
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ABOS
97 funds and institutions reported ABOS shares worth $128M at the end of Q2 2026, about 66% of the company. The largest holder is Ra Capital Management, L.P. with 29.1%.
Funds and institutions (13F) 66%Everyone else 34%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 20.99M | 29.07% | $56.1M | No change |
| Sands Capital Alternatives, LLC | 3.72M | 5.15% | $9.9M | No change |
| BlackRock, Inc. | 2.49M | 3.45% | $6.6M | +1296% |
| Alyeska Investment Group, L.P. | 2.45M | 3.40% | $6.6M | No change |
| Franklin Resources Inc | 2.31M | 3.19% | $6.2M | No change |
| ADAR1 Capital Management, LLC | 2.11M | 2.92% | $5.6M | -2% |
| Vanguard Capital Management LLC | 1.67M | 2.32% | $4.5M | +11% |
| Knollwood Investment Advisory, LLC | 1.63M | 2.26% | $4.3M | No change |
| Geode Capital Management, LLC | 1.14M | 1.58% | $3M | +174% |
| Ikarian Capital, LLC | 1.05M | 1.46% | $2.8M | No change |
| Hudson Bay Capital Management LP | 955,000 | 1.32% | $2.5M | -1% |
| Pathstone Holdings, LLC | 859,110 | 1.19% | $2.3M | No change |
| Renaissance Technologies LLC | 675,025 | 0.93% | $1.8M | +42% |
| Two Sigma Investments, LP | 622,882 | 0.86% | $1.7M | +17% |
| State Street Corp | 600,528 | 0.83% | $1.6M | +296% |
| Northern Trust Corp | 360,744 | 0.50% | $963K | +380% |
| Vanguard Portfolio Management LLC | 320,795 | 0.44% | $857K | New |
| Dimensional Fund Advisors LP | 291,559 | 0.40% | $779K | +143% |
| Vanguard Fiduciary Trust Co | 291,240 | 0.40% | $778K | +46% |
| Bank of America Corp | 274,781 | 0.38% | $734K | -14% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ABOS insiders reported $0 of open-market purchases and $592K of sales. 15% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | Derrell Porter | Director | Sale | 13,040 | $2.33 | $30.4K | Form 4 |
| Jun 16, 2026 | Derrell Porter | Director | Sale | 12,800 | $2.33 | $29.8K | Form 4 |
| Jun 15, 2026 | Derrell Porter | Director | Sale | 6,460 | $2.35 | $15.2K | Form 4 |
| Jun 9, 2026 | Nathan B Fountain | Director | Sale | 6,400 | $2.23 | $14.3K | Form 4 |
| Mar 6, 2026 | Derek M Meisner | Chief Legal Officer & Co | Sale plan | 2,090 | $3.26 | $6.8K | Form 4 |
| Feb 27, 2026 | Derek M Meisner | Chief Legal Officer & Co | Sale plan | 9,406 | $3.01 | $28.3K | Form 4 |
| Jan 28, 2026 | Derek M Meisner | Chief Legal Officer & Co | Sale plan | 2,671 | $3.00 | $8K | Form 4 |
| Jan 26, 2026 | Derek M Meisner | Chief Legal Officer & Co | Sale plan | 15,085 | $3.00 | $45.3K | Form 4 |
| Jan 23, 2026 | Derek M Meisner | Chief Legal Officer & Co | Sale | 5,633 | $1.90 | $10.7K | Form 4 |
| Jan 22, 2026 | Derek M Meisner | Chief Legal Officer & Co | Sale | 1,054 | $1.84 | $1.9K | Form 4 |
| Jan 22, 2026 | Eric Siemers | Chief Medical Officer | Sale | 895 | $1.82 | $1.6K | Form 4 |
| Jan 22, 2026 | Matt Zuga | CFO | Sale | 1,687 | $1.86 | $3.1K | Form 4 |
| Jan 22, 2026 | Daniel Joseph OConnell | CEO | Sale | 2,689 | $1.88 | $5.1K | Form 4 |
| Jan 22, 2026 | Russell Barton | Chief Operating Officer | Sale | 462 | $1.84 | $850 | Form 4 |
| Jan 21, 2026 | Derek M Meisner | Chief Legal Officer & Co | Sale | 2,247 | $1.81 | $4.1K | Form 4 |
| Jan 21, 2026 | Eric Siemers | Chief Medical Officer | Sale | 2,331 | $1.80 | $4.2K | Form 4 |
| Jan 21, 2026 | Matt Zuga | CFO | Sale | 2,473 | $1.81 | $4.5K | Form 4 |
| Jan 21, 2026 | Daniel Joseph OConnell | CEO | Sale | 9,346 | $1.81 | $16.9K | Form 4 |
| Jan 21, 2026 | Russell Barton | Chief Operating Officer | Sale | 2,315 | $1.81 | $4.2K | Form 4 |
| Jan 12, 2026 | Derek M Meisner | Chief Legal Officer & Co | Sale | 8,548 | $1.71 | $14.6K | Form 4 |
| Jan 12, 2026 | Daniel Joseph OConnell | CEO | Sale | 5,388 | $1.73 | $9.3K | Form 4 |
| Jan 9, 2026 | Derek M Meisner | Chief Legal Officer & Co | Sale | 5,200 | $1.76 | $9.2K | Form 4 |
| Jan 9, 2026 | Daniel Joseph OConnell | CEO | Sale | 12,941 | $1.76 | $22.8K | Form 4 |
| Jan 8, 2026 | Matt Zuga | CFO | Sale | 6,888 | $1.82 | $12.5K | Form 4 |
| Jan 8, 2026 | Russell Barton | Chief Operating Officer | Sale | 3,530 | $1.86 | $6.6K | Form 4 |
| Jan 8, 2026 | Derek M Meisner | Chief Legal Officer & Co | Sale | 30,092 | $1.82 | $54.8K | Form 4 |
| Jan 8, 2026 | Derek M Meisner | Chief Legal Officer & Co | Sale | 6,819 | $1.82 | $12.4K | Form 4 |
| Jan 8, 2026 | Daniel Joseph OConnell | CEO | Sale | 8,143 | $1.82 | $14.8K | Form 4 |
| Jan 8, 2026 | James J. Doherty | President | Sale | 6,467 | $1.82 | $11.8K | Form 4 |
| Jan 7, 2026 | James J. Doherty | President | Sale | 1,700 | $1.99 | $3.4K | Form 4 |
| Jan 7, 2026 | Amy Schacterle | Chief Regulatory Officer | Sale | 1,097 | $1.98 | $2.2K | Form 4 |
| Jan 7, 2026 | Matt Zuga | CFO | Sale | 4,105 | $2.00 | $8.2K | Form 4 |
| Jan 7, 2026 | Daniel Joseph OConnell | CEO | Sale | 37,755 | $1.99 | $75.1K | Form 4 |
| Jan 7, 2026 | Derek M Meisner | Chief Legal Officer & Co | Sale | 10,070 | $1.99 | $20K | Form 4 |
| Jan 6, 2026 | Matt Zuga | CFO | Sale | 5,100 | $1.97 | $10K | Form 4 |
| Jan 6, 2026 | Eric Siemers | Chief Medical Officer | Sale | 6,834 | $1.97 | $13.5K | Form 4 |
| Jan 6, 2026 | Daniel Joseph OConnell | CEO | Sale | 5,102 | $1.97 | $10.1K | Form 4 |
| Jan 6, 2026 | Derek M Meisner | Chief Legal Officer & Co | Sale | 7,097 | $1.97 | $14K | Form 4 |
| Jan 6, 2026 | Derek M Meisner | Chief Legal Officer & Co | Sale | 3,801 | $1.97 | $7.5K | Form 4 |
| Jan 6, 2026 | Russell Barton | Chief Operating Officer | Sale | 3,618 | $1.97 | $7.1K | Form 4 |
| Jan 5, 2026 | Matt Zuga | CFO | Sale | 4,000 | $1.96 | $7.8K | Form 4 |
| Jan 5, 2026 | Daniel Joseph OConnell | CEO | Sale | 4,649 | $1.97 | $9.2K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Derek M Meisner | Chief Legal Officer & Corp Sec | – | $238K | Mar 6, 2026 |
| Daniel Joseph OConnell | Chief Executive Officer, Director | – | $163K | Jan 22, 2026 |
| Derrell Porter | Director | – | $75.4K | Jun 17, 2026 |
| Matt Zuga | CFO & Chief Business Officer | – | $46.2K | Jan 22, 2026 |
| Eric Siemers | Chief Medical Officer | – | $19.3K | Jan 22, 2026 |
| Russell Barton | Chief Operating Officer | – | $18.7K | Jan 22, 2026 |
| James J. Doherty | President and CDO | – | $15.2K | Jan 8, 2026 |
| Nathan B Fountain | Director | – | $14.3K | Jun 9, 2026 |
| Amy Schacterle | Chief Regulatory Officer | – | $2.2K | Jan 7, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ABOS short interest
Moderate short interest. 6.3% of ABOS shares are sold short: about 1 share in 16. Over the last 12 reports the number of shares short went up 161%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 4.56M ABOS shares were sold short, 6.3% of the shares outstanding, up 47.4% from the report before. At the average daily volume of 6.86M shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 4.56M | 6.30% | +47% | 6.86M | 1.0 |
| Oct 15, 2026 | 3.09M | 4.27% | +0% | 569,571 | 5.4 |
| Sep 30, 2026 | 3.08M | 4.26% | +10% | 641,518 | 4.8 |
| Sep 15, 2026 | 2.80M | 3.88% | -11% | 343,829 | 8.2 |
| Aug 31, 2026 | 3.16M | 4.37% | -2% | 384,006 | 8.2 |
| Aug 14, 2026 | 3.23M | 4.46% | -4% | 310,001 | 10.4 |
| Jul 31, 2026 | 3.37M | 4.66% | +20% | 355,781 | 9.5 |
| Jul 15, 2026 | 2.81M | 3.90% | +1% | 374,875 | 7.5 |
| Jun 30, 2026 | 2.79M | 3.86% | +48% | 1.07M | 2.6 |
| Jun 15, 2026 | 1.89M | 2.61% | -0% | 321,419 | 5.9 |
| May 29, 2026 | 1.89M | 2.62% | +8% | 344,819 | 5.5 |
| May 15, 2026 | 1.75M | 2.42% | +4% | 273,487 | 6.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Acumen Pharmaceuticals company events
Acumen Pharmaceuticals filed 11 reports on Form 8-K in the last 12 months, 1 of them about an important change (job cuts). The latest was on Nov 5, 2026.
- Nov 5, 2026Job cutsAnnounced job cuts or other exit costs. Filing
- Oct 30, 2026AnnouncementOf this Current Report on Form 8-K (this “Report”). Filing
- Oct 26, 2026ResultsReleased financial results. Filing
- Sep 16, 2026AnnouncementShared information with investors. Filing
- Aug 12, 2026ResultsReleased financial results. Filing
- Jun 16, 2026AnnouncementThe Company announced the nomination of two EBD development candidates for the treatment of AD pursuant to its collaboration agreement with JCR and the exercise of its option pursuant to the collaboration agreement to license and develop such development candidates. Filing
- Jun 3, 2026VoteReported shareholder vote results. Filing
- May 12, 2026ResultsReleased financial results. Filing
- Mar 26, 2026ResultsReleased financial results. Filing
- Mar 16, 2026AgreementAcumen Pharmaceuticals, Inc. entered into a Securities Purchase Agreement with certain institutional accredited investors named therein (each, an “ Investor ” and collectively, the “ Investors ”), pursuant to which the Company agreed to sell to the Investors, in a private placement, 10,833,331… Filing
- Jan 12, 2026AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Acumen Pharmaceuticals financials
Famous investors that hold ABOS
2 of the 50 well-known investors we track reported holding ABOS in their latest 13F filing. The largest position is Jim Simons's, worth $1.4M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 614,654 | $1.4M | 0.0% | -9% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 37,990 | $84.3K | 0.0% | -26% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Acumen Pharmaceuticals, Inc. (ABOS) stock
Who owns the most ABOS stock?
The largest reported owner of Acumen Pharmaceuticals, Inc. (ABOS) is Ra Capital Management, L.P., with 29.1% of the company. In total, 97 funds and institutions reported holding ABOS at the end of Q2 2026, together about 66% of the shares. See the largest owners.
Are ABOS insiders buying or selling?
In the last 12 months, ABOS insiders reported no open-market purchases and 42 sales worth $592K. The latest trade was on Jun 17, 2026. See every trade.
What is the short interest in ABOS?
As of Oct 30, 2026, 4.56M ABOS shares were sold short, 6.3% of the shares outstanding, up 47.4% from the report before. At the average daily volume of 6.86M shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Which famous investors hold ABOS?
2 of the 50 well-known investors we track reported ABOS in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $1.4M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.